Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate

Author: Benzinga Newsdesk | March 14, 2024 04:31pm
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50) by 18 percent. The company reported quarterly sales of $1.676 million which beat the analyst consensus estimate of $1.632 million by 2.70 percent. This is a 110.55 percent increase over sales of $796.000 thousand the same period last year.

Posted In: EVOK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist